More than 26 million people worldwide were estimated to be living with Alzheimer's disease in 2006, and it is estimated that the global prevalence of Alzheimer's disease will grow to more than 106 million by 2050.

Experts will consider emerging disease targets, use of biomarkers and imaging techniques in clinical trials, cognitive testing, translational medicine, as well as safety and regulatory issues. There will also be an update on progress of the recent Alzheimer's Disease Neuroimaging Initiative (ADNI).

Why should you attend this event? GAIN insight into appropriate safety measures HEAR the latest progress of ADNI UNDERSTAND how to design better CNS trials EVALUATE different end-point methods DISCOVER recent advances in disease method understanding and target identification Associated Events: Effective Project Management in Clinical Trials 24th November 2009, Crowne Plaza Hotel – London St. James, London